Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Powered by 
Analysis
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.16% |
| Mar 31, 2026 | 17.28% |
| Dec 31, 2025 | 38.07% |
| Sep 30, 2025 | 17.35% |
| Jun 30, 2025 | 34.72% |
| Mar 31, 2025 | 21.66% |
| Dec 31, 2024 | 62.64% |
| Sep 30, 2024 | 15.87% |
| Jun 30, 2024 | 17.67% |
| Mar 31, 2024 | 20.11% |
| Dec 31, 2023 | -56.27% |
| Sep 30, 2023 | 20.27% |
| Jun 30, 2023 | 17.98% |
| Mar 31, 2023 | 19.58% |
| Dec 31, 2022 | -39.05% |
| Sep 30, 2022 | 3.36% |
| Jun 30, 2022 | 48.63% |
| Mar 31, 2022 | -28.57% |
| Dec 31, 2021 | -40.19% |
| Sep 30, 2021 | -39.54% |